Physician profile
Mena Shehata
NPI 1609227255
$11,103.16
in general payments reported to CMS, 2019-2025
21 companies · $7,362 in 2025
The $7,362 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $270 · 2023: $751 · 2024: $2,721 · 2025: $7,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $3,070 · Travel and Lodging: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $3,070.08 |
| Travel and Lodging | $2,263.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,249.32 | 2024-2025 | |
| Glaxosmithkline, LLC. | $1,148.54 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $429.05 | 2022-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $245.52 | 2022-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Actelion Pharmaceuticals US, INC. | $150.00 | 2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $136.30 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $120.57 | 2023-2024 | |
| Genzyme Corporation | $90.27 | 2022-2025 | |
| Axsome Therapeutics, INC. | $78.32 | 2023-2024 | Sunosi |
| Astrazeneca Pharmaceuticals LP | $65.32 | 2022-2025 | Breztri, Fasenra, Tezspire |
| Merck Sharp & Dohme LLC | $63.74 | 2024 | Winrevair |
| Erbe USA INC | $50.00 | 2024 | Cryo2 |
| Mylan Specialty L.P. | $47.00 | 2022-2024 | Yupelri |
| Viatris Specialty LLC | $45.44 | 2025 | Yupelri |
| Amgen INC. | $45.09 | 2025 | Tezspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.25 | 2023-2024 | Ofev |
| Jazz Pharmaceuticals INC. | $36.65 | 2023 | |
| Baxter Healthcare | $21.38 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $15.13 | 2022 | |
| Genentech USA, INC. | $14.77 | 2023 | Xolair |
| Electromed, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mena Shehata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.